Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avichai Shimoni

Showing results (101-110 of 165) with videos related to

Pageof 17
Sort By:
Bone Marrow Transplantation|December 3, 2020
Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphomaIvetta Danylesko, Roni Shouval, Noga Shem-Tov, et al.
Haematologica|May 25, 2010
Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working PartyAndrea Bacigalupo, Gerard Socie', Edoardo Lanino, et al.
Transplantation and Cellular Therapy|February 26, 2022
Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphomaMeirav Kedmi, Roni Shouval, Shalev Fried, et al.
Haematologica|February 22, 2008
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myelomaJean El-Cheikh, Mauricette Michallet, Arnon Nagler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2017
Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow TransplantationAvichai Shimoni, Myriam Labopin, Bipin Savani, et al.
Leukemia & Lymphoma|August 11, 2023
Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphomaShalev Fried, Eden Shkury, Orit Itzhaki, et al.
Annals of Hematology|January 28, 2022
Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocolDanielle Fredman, Yakir Moshe, Ofir Wolach, et al.
Leukemia|June 17, 2018
Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamideAvichai Shimoni, Myriam Labopin, Francesca Lorentino, et al.
Rheumatology (Oxford, England)|April 5, 2026
Anti-CD19 CAR-T cell therapy as rescue treatment in systemic sclerosis relapsing after autologous hematopoietic stem cell transplantation: a case seriesDoron Rimar, Paula David, Elad Jacoby, et al.
Bone Marrow Transplantation|January 13, 2022
The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AMLAvichai Shimoni, Myriam Labopin, Emanuele Angelucci, et al.
Pageof 17

Showing results (101-110 of 165) with videos related to

Sort By:
Pageof 17
Bone Marrow Transplantation|December 3, 2020
Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphomaIvetta Danylesko, Roni Shouval, Noga Shem-Tov, et al.
Haematologica|May 25, 2010
Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working PartyAndrea Bacigalupo, Gerard Socie', Edoardo Lanino, et al.
Transplantation and Cellular Therapy|February 26, 2022
Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphomaMeirav Kedmi, Roni Shouval, Shalev Fried, et al.
Haematologica|February 22, 2008
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myelomaJean El-Cheikh, Mauricette Michallet, Arnon Nagler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2017
Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow TransplantationAvichai Shimoni, Myriam Labopin, Bipin Savani, et al.
Leukemia & Lymphoma|August 11, 2023
Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphomaShalev Fried, Eden Shkury, Orit Itzhaki, et al.
Annals of Hematology|January 28, 2022
Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocolDanielle Fredman, Yakir Moshe, Ofir Wolach, et al.
Leukemia|June 17, 2018
Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamideAvichai Shimoni, Myriam Labopin, Francesca Lorentino, et al.
Rheumatology (Oxford, England)|April 5, 2026
Anti-CD19 CAR-T cell therapy as rescue treatment in systemic sclerosis relapsing after autologous hematopoietic stem cell transplantation: a case seriesDoron Rimar, Paula David, Elad Jacoby, et al.
Bone Marrow Transplantation|January 13, 2022
The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AMLAvichai Shimoni, Myriam Labopin, Emanuele Angelucci, et al.
Pageof 17